Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist September 25, 2020
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors September 10, 2020
GRAIL Announces Filing of Registration Statement for Proposed Initial Public Offering September 9, 2020
